Covid-19 drug development to include AI by Iktos and SRI.

Follow the latest updates of the outbreak on our timeline. Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza. Iktos will combine its generative modelling technology with SRI's fully automated synthetic chemistry platform called SynFini to design compounds and speed-up the identification of drug candidates. The Iktos AI technology leverages deep generative models for the accelerated drug discovery process, made possible via the automatic design of virtual molecules with the required characteristics of a new drug candidate. Iktos co-founder and CEO Yann Gaston-Mathé said: "Iktos generative AI technology has proven its value and potential to accelerate drug discovery programs in multiple collaborations with renowned pharmaceutical companies.